Biography
In his clinical practice, he treats patients with all forms of genitourinary cancer, including kidney, bladder, prostate, and testicular. He also regularly attends on the inpatient oncology service at Stanford Hospital.
With each patient, he is devoted to providing exceptional, humanistic care and has been recognized throughout his career for his humanism. As a medical student, he was named to the national Gold Humanism Honor Society and he received the Reza Gandjei Humanism Award as a medical resident at UCSF.
His research interests include novel therapies for genitourinary cancers, with a focus on urothelial cancer outcomes. He also has studied health care utilization and costs for end-of-life care of cancer patients.
Dr. Khaki has earned honors and recognition from the American Association for Cancer Research, American Society of Clinical Oncology, Bladder Cancer Advocacy Network, Conquer Cancer Foundation, and other organizations.
He has authored numerous articles on topics such as immunotherapy for urothelial cancer, management of cancer patients with COVID-19, and utilization of end-of-life care by cancer patients. In addition, he is an editor for HemOnc.org and theMednet, a physician-only online community where members share clinical questions and answers.
Professional Summary
Education & Certifications
- Residency: UCSF Dept of Internal Medicine (2016) CA
- Board Certification: American Board of Internal Medicine, Hematology (2020)
- Board Certification: American Board of Internal Medicine, Medical Oncology (2020)
- Medical Education: University of California San Diego School of Medicine (2013) CA
- Board Certification, American Board of Internal Medicine, Oncology
- Board Certification, American Board of Internal Medicine, Hematology
- Board Certification, American Board of Internal Medicine, Internal Medicine
- Fellowship, University of Washington, Seattle, Hematology/Oncology
- M.S., University of Washington School of Public Health, Epidemiology (2020)
- Fellowship: Fred Hutchinson Cancer Research Center (2020) WA
Honors & Awards
- Conquer Cancer Foundation Merit Award, American Society of Clinical Oncology (ASCO) (2019 (ASCO Quality Symposium))
- John Quale Travel Fellowship, Bladder Cancer Advocacy Network (BCAN) (2020)
- Reza Gandjei Resident Humanism Award, University of California, San Francisco (2016)
- San Antonio Breast Cancer Symposium Clinical Scholar Award, San Antonio Breast Cancer Symposium (2020)
Administrative Appointments
- Unit Based Medical Director, Stanford Healthcare (2021 - Present)
Publications
-
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y., Rubinstein, S. M., Rivera, D. R., … Warner, J. L. (2020). Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet (London, England). -
Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and Cancer Consortium (CCC19) cohort study.
Rivera, D. R., Peters, S., Panagiotou, O. A., Shah, D. P., Kuderer, N. M., Hsu, C.-Y., … Warner, J. L. (2020). Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and Cancer Consortium (CCC19) cohort study. Cancer Discovery. -
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.
Khaki, A. R., Li, A., Diamantopoulos, L. N., Miller, N. J., Carril-Ajuria, L., Castellano, D., … Grivas, P. (2021). A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. European Urology Oncology. -
Use of Real-World Electronic Health Records to Estimate Risk, Risk Factors, and Disparities for COVID-19 in Patients With Cancer.
Desai, A., Khaki, A. R., & Kuderer, N. M. (2020). Use of Real-World Electronic Health Records to Estimate Risk, Risk Factors, and Disparities for COVID-19 in Patients With Cancer. JAMA Oncology. -
Loose Regulatory Standards Portend a New Era of Imprecision Oncology.
Khaki, A. R. (2021). Loose Regulatory Standards Portend a New Era of Imprecision Oncology. Cancer Investigation, 1–4. -
Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program.
Diamantopoulos, L. N., Holt, S. K., Khaki, A. R., Sekar, R. R., Gadzinski, A., Nyame, Y. A., … Wright, J. L. (2020). Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program. Clinical Genitourinary Cancer. -
Gender Differences in Faculty Rank and Subspecialty Choice among Academic Medical Oncologists.
Graham, L. S., Sokolova, A. O., Khaki, A. R., Wu, Q. V., & Davidson, N. E. (2021). Gender Differences in Faculty Rank and Subspecialty Choice among Academic Medical Oncologists. Cancer Investigation, 39(1), 21–24. -
Comparison of Health Care Utilization at the End of Life Among Patients With Cancer in Alberta, Canada, Versus Washington State.
Khaki, A. R., Xu, Y., Cheung, W. Y., Li, L., Fedorenko, C., Grivas, P., … Shankaran, V. (2020). Comparison of Health Care Utilization at the End of Life Among Patients With Cancer in Alberta, Canada, Versus Washington State. JCO Oncology Practice, 16(12), e1543–e1552. -
Immunotherapy-based combination strategies for advanced urothelial cancer: A long quest.
Khaki, A. R., Agarwal, N., Pal, S. K., & Grivas, P. (2020). Immunotherapy-based combination strategies for advanced urothelial cancer: A long quest. Cancer, 126(20), 4446–50. -
Untangling the Multidisciplinary Care Web: Streamlining Care Through an Immune-Related Adverse Events (IRAE) Tumor Board.
Kennedy, L. C., Wong, K. M., Kamat, N. V., Khaki, A. R., Bhatia, S., Thompson, J. A., & Grivas, P. (2020). Untangling the Multidisciplinary Care Web: Streamlining Care Through an Immune-Related Adverse Events (IRAE) Tumor Board. Targeted Oncology, 15(4), 541–48. -
Central Nervous System Metastasis in Patients With Urothelial Carcinoma: Institutional Experience and a Comprehensive Review of the Literature.
Diamantopoulos, L. N., Khaki, A. R., Sonpavde, G. P., Venur, V. A., Yu, E. Y., Wright, J. L., & Grivas, P. (2020). Central Nervous System Metastasis in Patients With Urothelial Carcinoma: Institutional Experience and a Comprehensive Review of the Literature. Clinical Genitourinary Cancer, 18(3), e266–e276. -
Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study.
Miller, N. J., Khaki, A. R., Diamantopoulos, L. N., Bilen, M. A., Santos, V., Agarwal, N., … Grivas, P. (2020). Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. The Journal of Urology, 204(1), 63–70. -
Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.
Khaki, A. R., Li, A., Diamantopoulos, L. N., Bilen, M. A., Santos, V., Esther, J., … Grivas, P. (2020). Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. Cancer, 126(6), 1208–16. -
Clinical Risk During the Evaluation of Genomic Risk for Hormone-Sensitive Breast Cancer: Ignoring Valuable Data.
Khaki, A. R., Gadi, V. K., & Prasad, V. (2019). Clinical Risk During the Evaluation of Genomic Risk for Hormone-Sensitive Breast Cancer: Ignoring Valuable Data. Journal of the National Comprehensive Cancer Network : JNCCN, 17(12), 1456–58. -
Plasmacytoid Urothelial Carcinoma: Response to Chemotherapy and Oncologic Outcomes
Diamantopoulos, L. N., Khaki, A. R., Grivas, P., Gore, J. L., Schade, G. R., Hsieh, A. C., … Wright, J. L. (2020). Plasmacytoid Urothelial Carcinoma: Response to Chemotherapy and Oncologic Outcomes. BLADDER CANCER, 6(1), 71–81. -
Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis
Di Tanna, G. L., Khaki, A. R., Theron, G., McCarthy, K., Cox, H., Mupfumi, L., … Bandason, T. (2019). Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis. LANCET GLOBAL HEALTH, 7(2), E191–E199. -
Association of Renin and Aldosterone With Ethnicity and Blood Pressure: The Multi-Ethnic Study of Atherosclerosis
Rifkin, D. E., Khaki, A. R., Jenny, N. S., McClelland, R. L., Budoff, M., Watson, K., … Allison, M. A. (2014). Association of Renin and Aldosterone With Ethnicity and Blood Pressure: The Multi-Ethnic Study of Atherosclerosis. AMERICAN JOURNAL OF HYPERTENSION, 27(6), 801–10. -
Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy.
Diamantopoulos, L. N., Sekar, R. R., Holt, S. K., Khaki, A. R., Miller, N. J., Gadzinski, A., … Wright, J. L. (2021). Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy. Urologic Oncology. -
Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes.
Esagian, S. M., Khaki, A. R., Diamantopoulos, L. N., Carril-Ajuria, L., Castellano, D., De Kouchkovsky, I., … Grivas, P. (2021). Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. BJU International. -
Sarcomatoid urothelial carcinoma: Oncologic outcomes from a tertiary center and SEER-Medicare data.
Sekar, R. R., Diamantopoulos, L. N., Khaki, A. R., Vakar-Lopez, F., Tretiakova, M. S., Psutka, S. P., … Wright, J. L. (2020). Sarcomatoid urothelial carcinoma: Oncologic outcomes from a tertiary center and SEER-Medicare data. JOURNAL OF CLINICAL ONCOLOGY, 38(15). -
Perioperative blood transfusion and postoperative outcomes in patients undergoing radical cystectomy for bladder cancer.
Diamantopoulos, L. N., Sekar, R. R., Khaki, A. R., Miller, N., Gadzinski, A. J., Psutka, S. P., … Wright, J. L. (2020). Perioperative blood transfusion and postoperative outcomes in patients undergoing radical cystectomy for bladder cancer. JOURNAL OF CLINICAL ONCOLOGY, 38(15). -
Emerging clinical phenotype of bone metastatic urothelial cancer (mUC): Association of early osseous metastases (EOM) and outcomes.
Nelson, A. A., Cronk, R., Szabo, A., Lemke, E., Giever, T. A., Burfeind, J. D., … Hoimes, C. J. (2020). Emerging clinical phenotype of bone metastatic urothelial cancer (mUC): Association of early osseous metastases (EOM) and outcomes. JOURNAL OF CLINICAL ONCOLOGY, 38(15). -
Perioperative Immunotherapy in Muscle-invasive Bladder Cancer.
Tripathi, A., Khaki, A. R., & Grivas, P. (2021). Perioperative Immunotherapy in Muscle-invasive Bladder Cancer. European Urology Oncology. -
Outcomes of Patients with Sarcoma and COVID-19 Infection: A Single Institution Cohort Analysis.
Wagner, M. J., Pollack, S. M., Cranmer, L. D., Thompson, M. J., Maxwell, S., Wright, S., … Loggers, E. T. (2021). Outcomes of Patients with Sarcoma and COVID-19 Infection: A Single Institution Cohort Analysis. Cancer Investigation, 1–11. -
Characteristics and outcomes of SARS-CoV-2 infection in patients with invasive breast cancer (BC) from the COVID-19 and cancer consortium (CCC19) cohort study
Khaki, A. R., Shah, D. P., Lustberg, M. B., Accordino, M. K., Stover, D. G., Nagaraj, G., … Vinayak, S. (2021). Characteristics and outcomes of SARS-CoV-2 infection in patients with invasive breast cancer (BC) from the COVID-19 and cancer consortium (CCC19) cohort study. CANCER RESEARCH, 81(4). -
Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer.
Khaki, A. R., Shan, Y., Nelson, R. E., Kaul, S., Gore, J. L., Grivas, P., & Williams, S. B. (2021). Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer. Urologic Oncology. -
Association between sites of metastases (mets) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC).
Makrakis, D., Diamantopoulos, L. N., Koshkin, V. S., Alva, A. S., Bilen, M. A., Stewart, T. F., … Khaki, A. R. (2021). Association between sites of metastases (mets) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC). JOURNAL OF CLINICAL ONCOLOGY, 39(6). -
Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition (ICI) versus cisplatin-based chemotherapy (CBC) in muscle-invasive bladder cancer (MIBC).
Khaki, A. R., Shan, Y., Nelson, R., Kaul, S., Gore, J. L., Grivas, P., & Williams, S. B. (2021). Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition (ICI) versus cisplatin-based chemotherapy (CBC) in muscle-invasive bladder cancer (MIBC). JOURNAL OF CLINICAL ONCOLOGY, 39(6). -
Association between prior radical surgery (RS) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC).
Makrakis, D., Castellano, D., de Kouchkov, I., Park, J. J., Bilen, M. A., Agarwal, N., … Khaki, A. R. (2021). Association between prior radical surgery (RS) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC). JOURNAL OF CLINICAL ONCOLOGY, 39(6). -
Racial diversity and reporting in FDA registration trials for genitourinary (GU) cancers from 2006-20.
Lythgoe, M., Julve, M., Krell, J., Savage, P., Grivas, P., & Khaki, A. R. (2021). Racial diversity and reporting in FDA registration trials for genitourinary (GU) cancers from 2006-20. JOURNAL OF CLINICAL ONCOLOGY, 39(6). -
Severe-COVID-19 and mortality among patients (pts) with prostate cancer (PCa) receiving androgen deprivation therapy (ADT).
Tucker, M. D., Schmidt, A. L., Hsu, C.-Y., Shyr, Y., Armstrong, A. J., Bakouny, Z., … McKay, R. R. (2021). Severe-COVID-19 and mortality among patients (pts) with prostate cancer (PCa) receiving androgen deprivation therapy (ADT). JOURNAL OF CLINICAL ONCOLOGY, 39(6). -
Immune checkpoint inhibitors (ICI) in advanced upper tract and lower tract urothelial carcinoma (UC): A comparison of outcomes.
Esagian, S. M., Khaki, A. R., Carril-Ajuria, L., Park, J. J., Bilen, M. A., Stewart, T. F., … Petros, G. (2021). Immune checkpoint inhibitors (ICI) in advanced upper tract and lower tract urothelial carcinoma (UC): A comparison of outcomes. JOURNAL OF CLINICAL ONCOLOGY, 39(6). -
Efficacy of enfortumab vedotin in advanced urothelial cancer: Retrospective analysis of the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) Study.
Koshkin, V. S., Sun Yilun, Freeman, D., Osterman, C. K., Su, C., Natesan, D., … Alva, A. S. (2021). Efficacy of enfortumab vedotin in advanced urothelial cancer: Retrospective analysis of the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) Study. JOURNAL OF CLINICAL ONCOLOGY, 39(6). -
Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors.
Michailidou, D., Khaki, A. R., Morelli, M. P., Diamantopoulos, L., Singh, N., & Grivas, P. (2021). Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors. Scientific Reports, 11(1), 9029. -
Early Bone Metastases are Associated with Worse Outcomes in Metastatic Urothelial Carcinoma
Nelson, A. A., Cronk, R. J., Lemke, E. A., Szabo, A., Khaki, A. R., Diamantopoulos, L. N., … Hoimes, C. J. (2021). Early Bone Metastases are Associated with Worse Outcomes in Metastatic Urothelial Carcinoma. BLADDER CANCER, 7(1), 33–42. -
Utilization of Systemic Therapy in Patients With Cancer Near the End of Life in the Pre- Versus Postimmune Checkpoint Inhibitor Eras.
Khaki, A. R., Chennupati, S., Fedorenko, C., Li, L., Sun, Q., Grivas, P., … Shankaran, V. (2021). Utilization of Systemic Therapy in Patients With Cancer Near the End of Life in the Pre- Versus Postimmune Checkpoint Inhibitor Eras. JCO Oncology Practice, OP2001050. -
Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomes.
Diamantopoulos, L. N., Khaki, A. R., Grivas, P., Gore, J. L., Schade, G. R., Hsieh, A. C., … Wright, J. L. (2020). Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomes. Bladder Cancer (Amsterdam, Netherlands), 6(1), 71–81. -
Clinical and Virologic Characteristics and Outcomes of Coronavirus Disease 2019 at a Cancer Center.
Yoke, L. H., Lee, J. M., Krantz, E. M., Morris, J., Marquis, S., Bhattacharyya, P., … Liu, C. (2021). Clinical and Virologic Characteristics and Outcomes of Coronavirus Disease 2019 at a Cancer Center. Open Forum Infectious Diseases, 8(6), ofab193. -
Immunotherapy in Patients With Poor Performance Status: The Jury Is Still Out on This Special Population.
Khaki, A. R., Glisch, C., & Petrillo, L. A. (2021). Immunotherapy in Patients With Poor Performance Status: The Jury Is Still Out on This Special Population. JCO Oncology Practice, OP2100397. -
Use of Second-line Immunotherapy in Control Arms of Randomized Clinical Trials in Kidney Cancer: A Systematic Review.
Sharp, J., Khaki, A. R., & Prasad, V. (2021). Use of Second-line Immunotherapy in Control Arms of Randomized Clinical Trials in Kidney Cancer: A Systematic Review. JAMA Network Open, 4(9), e2124728. -
Association of prior local therapy and outcomes with PD(L)1 inhibitor in advanced urothelial cancer.
Makrakis, D., Talukder, R., Diamantopoulos, L. N., Carril-Ajuria, L., Castellano, D., De Kouchkovsky, I., … Khaki, A. R. (2021). Association of prior local therapy and outcomes with PD(L)1 inhibitor in advanced urothelial cancer. BJU International. -
Racial diversity and reporting in FDA registration trials for thoracic malignancies from 2006 to 2020
Chiang, R. S., Glover, M., Hui, G., Desai, A., Wakelee, H. A., Lythgoe, M., & Khaki, A. R. (2021). Racial diversity and reporting in FDA registration trials for thoracic malignancies from 2006 to 2020. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Association of treatment type with patient-reported quality of life in cancer distress screening
Roy, M., Rosenthal, S., Shah, M. P., Khaki, A. R., Bozkurt, S., Seto, T., … Ramchandran, K. (2021). Association of treatment type with patient-reported quality of life in cancer distress screening. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Outcomes of Patients with COVID-19 from a Specialized Cancer Care Emergency Room.
Nath, S. S., Yadav, N. U., Derkach, A., Perez-Johnston, R., Tachiki, L., Maguire, K., … Groeger, J. (2021). Outcomes of Patients with COVID-19 from a Specialized Cancer Care Emergency Room. Cancer Investigation, 1–9. -
Disparity of Race Reporting in FDA Drug Approvals for Urinary System Cancers from 2006 to 2021.
Glover, M., Hui, G., Chiang, R., Savage, P., Krell, J., Julve, M., … Khaki, A. R. (2021). Disparity of Race Reporting in FDA Drug Approvals for Urinary System Cancers from 2006 to 2021. BJU International. -
Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19.
Schmidt, A. L., Tucker, M. D., Bakouny, Z., Labaki, C., Hsu, C.-Y., Shyr, Y., … McKay, R. R. (2021). Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19. JAMA Network Open, 4(11), e2134330. -
Code status and outcomes in patients with cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) registry analysis.
Loggers, E. T., Wulff-Burchfield, E. M., Subbiah, I. M., Khaki, A. R., Egan, P., Farmakiotis, D., … Warner, J. L. (2021). Code status and outcomes in patients with cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) registry analysis. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Demographics, outcomes, and risk factors for patients (Pts) with sarcoma and COVID-19: A multi-institutional cohort analysis.
Wagner, M. J., Ingham, M., Painter, C., Chugh, R., Trent, J. C., Subbiah, V., … Davis, E. J. (2021). Demographics, outcomes, and risk factors for patients (Pts) with sarcoma and COVID-19: A multi-institutional cohort analysis. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Time intervals between US Food and Drug Administration (FDA) and European Medicines Agency (EMA) new cancer therapy approvals.
Lythgoe, M., Krell, J., Warner, J. L., Desai, A., & Khaki, A. R. (2021). Time intervals between US Food and Drug Administration (FDA) and European Medicines Agency (EMA) new cancer therapy approvals. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Patients' perception of meaning of life and needed support before and after cancer treatment initiation
Roy, M., Rosenthal, S., Shah, M., Khaki, A., Hernandez-Boussard, T., & Ramchandran, K. (2021). Patients' perception of meaning of life and needed support before and after cancer treatment initiation. QUALITY OF LIFE RESEARCH. SPRINGER. -
Efficacy of anti-PD(L)1 therapy for patients (Pts) with advanced urothelial carcinoma (aUC) with primary resistance to platinum-based chemotherapy (PC).
Stewart, T. F., Kotha, N. V., Dzimitrowicz, H. E., Makrakis, D., Khaki, A. R., Simon, N. I., … McKay, R. R. (2021). Efficacy of anti-PD(L)1 therapy for patients (Pts) with advanced urothelial carcinoma (aUC) with primary resistance to platinum-based chemotherapy (PC). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Outcomes of patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitors (ICIs): Associations with age, race, sex and smoking history.
Makrakis, D., Talukder, R., Carril, L., de Kouchkovsky, I., Park, J. J., Bilen, M. A., … Khaki, A. R. (2021). Outcomes of patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitors (ICIs): Associations with age, race, sex and smoking history. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
Koshkin, V. S., Henderson, N., James, M., Natesan, D., Freeman, D., Nizam, A., … Alva, A. S. (2021). Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. Cancer. -
Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin.
Talukder, R., Makrakis, D., Diamantopoulos, L. N., Carril-Ajuria, L., Castellano, D., De Kouchkovsky, I., … Khaki, A. R. (1800). Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. Clinical Genitourinary Cancer. -
Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicentre, Phase 2 Study.
Parikh, D. A., Khaki, A. R., & Williams, S. B. (2022). Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicentre, Phase 2 Study. European Urology. -
Long term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer.
Golla, V., Shan, Y., Farran, E. J., Stewart, C. A., Vu, K., Yu, A., … Williams, S. B. (2022). Long term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer. Urologic Oncology. -
Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: a cohort study from the COVID-19 and Cancer Consortium.
Elkrief, A., Hennessy, C., Kuderer, N. M., Rubinstein, S. M., Wulff-Burchfield, E., Rosovsky, R. P., … Wildes, T. M. (2022). Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: a cohort study from the COVID-19 and Cancer Consortium. The Lancet. Healthy Longevity. -
Association of renal cell carcinoma (RCC) metastatic to pancreas with a distinct molecular profile and immune cell population.
Chiang, R. S., Ashok, A., Mauer, E., Barrett, A., Hoerner, C. R., Khan, O. A., … Khaki, A. R. (2022). Association of renal cell carcinoma (RCC) metastatic to pancreas with a distinct molecular profile and immune cell population. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Long-term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer.
Golla, V., Shan, Y., Farran, E. J., Vu, K., Stewart, C. A., Khaki, A. R., … Williams, S. B. (2022). Long-term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Association of time to second-line (2L) immune-checkpoint inhibitors (ICI) and outcomes with ICIs in patients (pts) with advanced urothelial carcinoma (aUC).
Makrakis, D., Talukder, R., Dawsey, S., Carril, L., Stewart, T. F., Morales-Barrera, R., … Khaki, A. R. (2022). Association of time to second-line (2L) immune-checkpoint inhibitors (ICI) and outcomes with ICIs in patients (pts) with advanced urothelial carcinoma (aUC). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019.
Lythgoe, M. P., Desai, A., Gyawali, B., Savage, P., Krell, J., Warner, J. L., & Khaki, A. R. (2022). Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019. JAMA Network Open, 5(6), e2216183. -
Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.
Makrakis, D., Talukder, R., Lin, G. I., Diamantopoulos, L. N., Dawsey, S., Gupta, S., … Khaki, A. R. (2022). Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer. -
Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicentre, Phase 2 Study
Parikh, D. A., Kaki, A. R., & Williams, S. B. (2022). Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicentre, Phase 2 Study. EUROPEAN UROLOGY, 81(4), 429–430. -
Considerations in the reliability and fairness audits of predictive models for advance care planning
Lu, J., Sattler, A., Wang, S., Khaki, A. R., Callahan, A., Fleming, S., … Shah, N. (2022). Considerations in the reliability and fairness audits of predictive models for advance care planning. Frontiers in Digital Health. -
Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study.
Wagner, M. J., Hennessy, C., Beeghly, A., French, B., Shah, D. P., Croessmann, S., … Davis, E. J. (2022). Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study. Cancers, 14(17). -
Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma.
Talukder, R., Makrakis, D., Lin, G. I., Diamantopoulos, L. N., Dawsey, S., Gupta, S., … Khaki, A. R. (2022). Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer. -
Racial diversity and reporting in United States Food and Drug Administration registration trials for thoracic malignancies from 2006-2020.
Chiang, R. S., Desai, A., Glover, M. J., Hui, G., Ramchandran, K. J., Wakelee, H., … Khaki, A. R. (2022). Racial diversity and reporting in United States Food and Drug Administration registration trials for thoracic malignancies from 2006-2020. Cancer Investigation, 1–6. -
Immunotherapy for Urothelial Carcinoma: Focus on Clinical Utility of Nivolumab.
Chiang, R. S., Glover, M. J., Khaki, A. R., & Srinivas, S. (2022). Immunotherapy for Urothelial Carcinoma: Focus on Clinical Utility of Nivolumab. OncoTargets and Therapy, 15, 1259–1269. -
Use of systemic cancer treatments based on a validated survival prediction model in metastatic cancer.
Roy, M., Gensheimer, M. F., Chang, D. T., Singhal, S., & Khaki, A. R. (2022). Use of systemic cancer treatments based on a validated survival prediction model in metastatic cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Reducing inpatient mortality in patients with cancer through multidisciplinary review and targeted interventions.
Shah, M. P., Garrigues, S. K., Khaki, A. R., Hansen, J., Divi, V., & Blayney, D. W. (2022). Reducing inpatient mortality in patients with cancer through multidisciplinary review and targeted interventions. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Patient-reported distress at a cancer center during the COVID-19 pandemic.
Shah, M. P., Rosenthal, S., Roy, M., Khaki, A. R., Hernandez-Boussard, T., & Ramchandran, K. (2022). Patient-reported distress at a cancer center during the COVID-19 pandemic. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Using real-world data to assess variations in cost and healthcare utilization for patients diagnosed with bladder cancer.
Boehmer, L., Khaki, A. R., Carthon, B. C., Davis, N. B., Washington, S. L., Goltz, H. H., … Mangir, C. (2022). Using real-world data to assess variations in cost and healthcare utilization for patients diagnosed with bladder cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer.
Gensheimer, M. F., Gupta, D., Patel, M. I., Fardeen, T., Hildebrand, R., Teuteberg, W., … Ramchandran, K. (2022). Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer. JCO Oncology Practice, OP2200128. -
Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.
Makrakis, D., Bakaloudi, D. R., Talukder, R., Lin, G. I., Diamantopoulos, L. N., Jindal, T., … Koshkin, V. S. (2022). Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer. -
Adjuvant checkpoint inhibitor trials: Is disease-free survival an appropriate endpoint?
Khaki, A. R., Lythgoe, M. P., & Prasad, V. (2023). Adjuvant checkpoint inhibitor trials: Is disease-free survival an appropriate endpoint? Journal of Cancer Policy, 35, 100402. -
Determinants of prognosis in metastatic urothelial carcinoma: a review of the literature
Hui, G., Khaki, A. R., & Grivas, P. (2022). Determinants of prognosis in metastatic urothelial carcinoma: a review of the literature. JOURNAL OF CANCER METASTASIS AND TREATMENT, 8. -
Geriatric assessment in the older adult with genitourinary cancer: A narrative review.
Singhal, S., Marwell, J. G., & Khaki, A. R. (2023). Geriatric assessment in the older adult with genitourinary cancer: A narrative review. Frontiers in Oncology, 13, 1124309. -
Immune related liver toxicity and potential risk factors: A case-control study
Storm, E. M., Makraki, D., Lin, G. I., Kennedy, L. C., Shah, E. E., Phipps, A. I., … Khaki, A. R. (2022). Immune related liver toxicity and potential risk factors: A case-control study. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Sarcomatoid Urothelial Carcinoma Is Associated With Limited Response to Neoadjuvant Chemotherapy and Poor Oncologic Outcomes After Radical Cystectomy.
Sekar, R. R., Diamantopoulos, L. N., Bakaloudi, D. R., Khaki, A. R., Grivas, P., Winters, B. R., … Wright, J. L. (2023). Sarcomatoid Urothelial Carcinoma Is Associated With Limited Response to Neoadjuvant Chemotherapy and Poor Oncologic Outcomes After Radical Cystectomy. Clinical Genitourinary Cancer. -
Patient-reported distress at a cancer center during the COVID-19 pandemic.
Shah, M. P., Rosenthal, S. W., Roy, M., Khaki, A. R., Hernandez-Boussard, T., & Ramchandran, K. (2023). Patient-reported distress at a cancer center during the COVID-19 pandemic. Scientific Reports, 13(1), 9581. -
Role of Underlying Liver Pathology in the Development of Immune-Related Hepatitis: A Case-Control Study.
Storm, E. M., Makrakis, D., Lin, G. I., Talukder, R., Bakaloudi, D. R., Shah, E. E., … Khaki, A. R. (2023). Role of Underlying Liver Pathology in the Development of Immune-Related Hepatitis: A Case-Control Study. Targeted Oncology. -
Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience.
Bakaloudi, D. R., Talukder, R., Lin, G. I., Makrakis, D., Diamantopoulos, L. N., Tripathi, N., … Grivas, P. (2023). Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience. Clinical Genitourinary Cancer. -
Implications of Contact Days in the Treatment of Relapsed Refractory Diffuse Large B-Cell Lymphoma.
Bojanini, L., Gupta, N., & Khaki, A. R. (2023). Implications of Contact Days in the Treatment of Relapsed Refractory Diffuse Large B-Cell Lymphoma. The Oncologist. -
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors.
El Zarif, T., Nassar, A. H., Pond, G. R., Zhuang, T. Z., Master, V., Nazha, B., … Sonpavde, G. P. (2023). Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors. Journal of the National Cancer Institute. -
Renal cell carcinoma with metastasis to the pancreas: Genomic signatures and clinical outcomes
Glover, M., Chiang, R. S., Hoerner, C. R., Khan, O. A., Kao, C.-S., Shah, S., … Khaki, A. R. (2023). Renal cell carcinoma with metastasis to the pancreas: Genomic signatures and clinical outcomes. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Outcomes with immune checkpoint inhibitors (ICI) in patients (pts) with MTAP alterations (alt) in advanced urothelial carcinoma (aUC).
Talukder, R., Bakaloudi, D. R., Lin, G. I., Enright, T., Leary, J. B., Makrakis, D., … Grivas, P. (2023). Outcomes with immune checkpoint inhibitors (ICI) in patients (pts) with MTAP alterations (alt) in advanced urothelial carcinoma (aUC). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Assessment of price variation in colorectal cancer screening procedures at US hospitals.
Paranjpe, I., Sharma, P., Wei, C., Puram, V., Kamat, S., & Khaki, A. R. (2023). Assessment of price variation in colorectal cancer screening procedures at US hospitals. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: a COVID-19 and cancer consortium (CCC19) cohort study.
Nagaraj, G., Vinayak, S., Khaki, A. R., Sun, T., Kuderer, N. M., Aboulafia, D. M., … Shah, D. P. (2023). Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: a COVID-19 and cancer consortium (CCC19) cohort study. ELife, 12. -
Clinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Cohort Study.
Nagaraj, G., Vinayak, S., Khaki, A. R., Sun, T., Kuderer, N. M., Aboulafia, D. M., … Shah, D. P. (2023). Clinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. MedRxiv : the Preprint Server for Health Sciences. -
The 2023 European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: A Critical Appraisal.
Hensley, P. J., Choudhury, A., Khaki, A. R., Grivas, P., & Kamat, A. M. (2023). The 2023 European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: A Critical Appraisal. European Urology. -
Phase 2 open label study of durvalumab with neoadjuvant chemotherapy in variant histology bladder cancer.
Khaki, A. R., Fan, A. C., Shah, S., Parikh, D. A., Chien, J., Moore, K., … Srinivas, S. (2023). Phase 2 open label study of durvalumab with neoadjuvant chemotherapy in variant histology bladder cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Outcomes with immune checkpoint inhibitor (ICI) therapy in patients with FGFR2/3 alterations in advanced urothelial carcinoma (aUC).
Talukder, R., Bakaloudi, D. R., Makrakis, D., Tripathi, N., Agarwal, N., Jindal, T., … Khaki, A. R. (2023). Outcomes with immune checkpoint inhibitor (ICI) therapy in patients with FGFR2/3 alterations in advanced urothelial carcinoma (aUC). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Response and outcomes of maintenance avelumab after platinum-based chemotherapy (PBC) in patients (pts) with advanced urothelial carcinoma (aUC): "Real world" experience.
Bakaloudi, D. R., Talukder, R., Makrakis, D., Agarwal, N., Tripathi, N., Bamias, A., … Grivas, P. (2023). Response and outcomes of maintenance avelumab after platinum-based chemotherapy (PBC) in patients (pts) with advanced urothelial carcinoma (aUC): "Real world" experience. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Biomarkers of response to enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
Jindal, T., Kilari, D., Alhalabi, O., Nizam, A., Khaki, A. R., Basu, A., … Koshkin, V. S. (2023). Biomarkers of response to enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Homologous recombination repair (HRR) mutation concordance between liquid biopsy (LB) and tumor tissue by NGS in a real-world prostate cancer (PC) database.
Shen, J., Wang, L., Khaki, A. R., Jimenez, R. E., Mauer, E., Stoppler, M. C., … Kohli, M. (2023). Homologous recombination repair (HRR) mutation concordance between liquid biopsy (LB) and tumor tissue by NGS in a real-world prostate cancer (PC) database. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy »
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer »
- Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC) »
- A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies »
Practice Locations
Urologic Cancer Program in Palo Alto Palo Alto, CA
Palo Alto, CAUrologic Cancer Program in Palo Alto
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Patient Reviews
(110 reviews)
View More »
Referring Physicians
PHYSICIAN HELPLINE
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology orders
- View referral status
- Access medical records